Skip to main content

Table 1 Clinical characteristics of study subjects stratified by Wnt16a insertion carriers versus non-carriers

From: Carriers of a novel frame-shift insertion in WNT16a possess elevatedpancreatic expression of TCF7L2

Trait Non carrier Carrier Pvalue
  Number 1377 657 -
  % Males 52 51 -
  Age (yrs) 53.4 ± 12.9 51.7 ± 12.1 0.004
Obesity    
  BMI (kg/m2) 26.8 ± 4.9 26.8 ± 5.1 0.930
  Weight (kg) 69.8 ± 14.0 70.0 ± 14.3 0.811
  Waist (cm) 93.6 ± 12.2 93.4 ± 12.0 0.704
  WHR 0.95 ± 0.08 0.95 ± 0.08 0.242
Metabolic    
  Fasting Blood Glucose mg/dL 120.7 ± 45.4 121.5 ± 45.4 0.736
  Insulin (μIU/mL) 6.9 (6.6-7.3) 7.5 (7.0-8.1) 0.081
  HOMA-IR 2.0 (1.9-2.2) 2.2 (2.1-2.4) 0.059
  C-peptide pg/mL 519.5 (473.7-569.7) 602.8 (525.6-691.4) 0.078
Inflammation    
  TNFα pg/mL 7.9 (7.4-8.5) 9.2 (8.2-10.2) 0.029
  MCP1 pg/mL 315.5 (296.7-335.6) 326.5 (297.9-357.8) 0.541
Lipid    
  Triglyceride mg/dL 149.0 ± 82.3 151.5 ± 85.9 0.542
  Total Cholesterol mg/dL 173.8 ± 52.9 179.2 ± 49.9 0.038
  HDL-C mg/dL 37.2 ± 14.7 37.9 ± 14.2 0.292
  LDL-C mg/dL 102.1 ± 40.0 104.9 ± 38.3 0.143
  1. WHR-Waist to hip ratio, LDL-C -low density lipoprotein cholesterol,HDL-C -high density lipoprotein cholesterol, BMI- body mass index,HOMA-IR -homeostasis model assessment for insulin resistance.